Viridian Therapeutics
VRDN
138 hedge funds and large institutions have $906M invested in Viridian Therapeutics in 2024 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 70 increasing their positions, 28 reducing their positions, and 16 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 28
25% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 16
1% more funds holding
Funds holding: 136 → 138 (+2)
4.03% less ownership
Funds ownership: 113.16% → 109.13% (-4%)
27% less capital invested
Capital invested by funds: $1.24B → $906M (-$338M)
42% less call options, than puts
Call options by funds: $3.99M | Put options by funds: $6.92M
80% less funds holding in top 10
Funds holding in top 10: 5 → 1 (-4)
Top Buyers
| 1 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$22.4M |
| 2 |
BlackRock
New York
|
+$13.3M |
| 3 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$12.5M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$9.69M |
| 5 |
MC
Maverick Capital
Dallas,
Texas
|
+$8.52M |
Top Sellers
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
-$29.6M |
| 2 |
PA
Perceptive Advisors
New York
|
-$28M |
| 3 |
State Street
Boston,
Massachusetts
|
-$23.8M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$12.3M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$11.6M |
VRDN Hedge Fund Activity: Q2 2024 in Review
138 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q2 2024, worth a combined $906M — down 27% from $1.24B a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new VRDN positions and 16 closed out — a net gain of 4 holders — while 70 added to existing stakes and 28 trimmed.
The largest buyer was Kynam Capital Management, adding an estimated $22.4M. The largest seller was Paradigm Biocapital Advisors, cutting an estimated $29.6M.
- 138 institutional investors held Viridian Therapeutics (VRDN) as of Q2 2024, up from 136 in Q1 2024.
- Funds reported $906M of Viridian Therapeutics stock for Q2 2024, down 27% quarter-over-quarter.
- 20 funds opened new Viridian Therapeutics positions in Q2 2024 and 16 closed out, a net change of +4 holders.
- The largest Viridian Therapeutics buyer in Q2 2024 was Kynam Capital Management, an estimated $22.4M added.
- The largest Viridian Therapeutics seller in Q2 2024 was Paradigm Biocapital Advisors, an estimated $29.6M sold.
Based on aggregated 13F filings for Q2 2024.